Radiation therapy and androgen deprivation in the management of high risk prostate cancer

International Braz J Urol

Volumn 37, Issue 2, 2011, Pages 161-175

  Dal Pra, Alan ^a   Cury, Fabio L ^a   Souhami, Luis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Androgen deprivation therapy; Combined treatment; High risk; Hormonal therapy; Prostate neoplasms; Radiotherapy

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER STAGING; HUMAN; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE TUMOR; RADIATION DOSE; REVIEW; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 79959297961     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000200003     Document Type: Review

References (75)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008; 15: 3866-71.
2. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR, et al.: Who is the average patient presenting with prostate cancer? Urology. 2005; 66(5 suppl): 76-82.
3. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al.: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003; 57: 915-28.
4. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 168: 9-12.
5. de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S: Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762. Prog Clin Biol Res. 1988; 260: 111-7.
6. [No authors listed]: Management of advanced cancer of prostate and bladder. Proceedings of a symposium on the tenth anniversary of EORTC, Leeds, England, October 3rd, 1986 and the Fifth Course in Urological Oncology, Erice, Sicily, November 28-December 4th, 1986. Prog Clin Biol Res. 1988; 260: 1-658.
7. [No authors listed]: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355: 1491-8.
8. [No authors listed]: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet. 1995 Jul 29; 346: 265-9.
9. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988; 14: 1085-91.
10. Granfors T, Modig H, Damber JE, Tomic R: Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol. 2006; 176: 544-7.
11. See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group: The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006; 132(suppl 1): S7-16.
12. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al.: Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005; 76: 4-10.
13. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al.: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74.
14. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al.: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 1990-6.
15. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al.: Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005; 23: 1192-9.
16. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al.: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8: 475-87.
17. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-9. Erratum in: JAMA. 2008; 299: 899-900.
18. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L, et al.: Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001; 8: 1314-22.
19. Zietman AL, Prince EA, Nakfoor BM, Park JJ: Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997; 38: 1067-70.
20. Zietman AL, Prince EA, Nakfoor BM, Shipley WU: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology. 1997; 49(3A Suppl): 74-83.
21. Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A: Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys. 2003; 57: 24-8.
22. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC: The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010; 105: 8-13.
23. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
24. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333: 1757-63.
25. Fukumura D, Jain RK: Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007; 74: 72-84.
26. Joseph IB, Isaacs JT: Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res. 1997; 57: 1054-7.
27. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT: Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997; 3: 2507-11.
28. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143: 401-9.
29. Borre M, Offersen BV, Nerstrøm B, Overgaard J: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer. 1998; 78: 940-4.
30. Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, et al.: Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009; 27: 5627-33.
31. Okihara K, Watanabe H, Kojima M: Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol. 1999; 25: 89-94.
32. Huang SF, Chang RF, Moon WK, Lee YH, Chen DR, Suri JS: Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images. IEEE Trans Med Imaging. 2008; 27: 320-30.
33. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, et al.: Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res. 2007; 67: 6022-5.
34. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF: Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl. 1992; 13: 457-64.
35. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, et al.: Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004; 173: 6098-108.
36. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243-52.
37. Hirsch FR, Hansen HH, Hansen M, Osterlind K, Vindeløv LL, Dombernowsky P, et al.: The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol. 1987; 5: 585-91.
38. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, et al.: The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004; 171: 1137-40.
39. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-7.
40. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-95.
41. Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, et al.: Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010; 77: 1046-52.
42. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al.: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-50.
43. McGowan D, Hunt D, Jones C, Amin M, Leibenhaut M, Husian S, et al.: Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA = 20: Initial Results of RTOG 94-08. Int J Radiat Oncol Biol Phys. 2010; 77: 1. Abstract: # LB 1.
44. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-74.
45. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-21.
46. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-90.
47. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
48. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360: 103-6.
49. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, et al.: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-8. Erratum in: J Clin Oncol. 2004; 22: 386.
50. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al.: Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-504.
51. Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005; 23: 800-7. Erratum in: J Clin Oncol. 2005; 23: 8921.
52. Souhami L, Bae K, Pilepich M, Sandler H: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol. 2009; 27: 2137-43.
53. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, et al.: Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 15-23.
54. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, et al.: Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 73: 327-33.
55. Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, et al.: Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys. 2010; 76: 23-30.
56. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al.: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21: 1904-11.
57. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al.: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-27.
58. D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, et al.: Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007; 109: 2004-10.
59. Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, et al.: Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study. Radiother Oncol. 2009; 90: 299-306.
60. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al.: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373: 301-8. Erratum in: Lancet. 2009; 373: 1174.
61. Warde PR, Mason MD, Sydes MR, Gospodarowicz MK, GP S, Kirkbride P, et al.: Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK,INT: T94-0110; NCT00002633). J Clin Oncol. 2010; 28(suppl): Abstract # CRA4504.
62. Mottet N, Peneau M, Mazeron J, Molinie V, Richaud P: Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. J Clin Oncol. 2010; 28(suppl): Abstract # 4505.
63. Zietman AL: Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008; 299: 898-9.
64. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, et al.: Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 980-8.
65. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238-44.
66. Alibhai SM, Gogov S, Allibhai Z: Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006; 60: 201-15.
67. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM: Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90: 6410-7.
68. Kim SO, Kang TW, Kwon D, Park K, Ryu SB: Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy. Int Braz J Urol. 2009; 35: 183-8; discussion 189.
69. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-56.
70. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al.: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110: 1493-500.
71. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 1516-24.
72. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al.: Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009; 27: 3452-8.
73. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 2420-5.
74. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302: 866-73.
75. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al.: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009; 27: 92-9.